Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (March 2019)
20 slides from Resonance Health's investor presentation, Mar 25, 2019
Slide 1: Investor Presentation March 2019
For personal use only INVESTOR PRESENTATION Resonance Health (ASX: RHT) is an Australian healthcare company MARCH 2019 specialising in the delivery and development of non-invasive medical imaging software and analysis services.
Slide 2: Resonance Health Limited (ASX: RHT)
2 ANNUAL REPORT TEMPLATE MINIMAL DESIGN 2016/2107 For personal use only Resonance Health Limited (ASX: RHT)
Slide 3: Disclaimer
INVESTOR PRESENTATION MARCH 2019 3 DISCLAIMER For personal use only This presentation has been prepared by Resonance Health Limited (“Resonance Health” or “Company”) only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a n
Slide 4: Corporate Profile
4 MARCH ANNUAL 2019 REPORT TEMPLATE INVESTOR PRESENTATION MINIMAL DESIGN 2016/2107 CORPORATE For personal use only PROFILE Resonance Health is an Resonance Health has established a Australian healthcare company global distribution network of over 480 specialising in the development hospital centres,
Slide 5: Corporate Structure
INVESTOR PRESENTATION MARCH 2019 5 CORPORATE ASX RHT(* at 12/3/19) For personal use only Share price 0.078* STRUCTURE Shares on issue 402.5m Options (0.03, 0.05,0.075,0.10c, Mar 21m 2021 expiry) Options (0.05,0.075c Sept 2021 0.5m Board & Management expiry) • Dr Martin Blake - Non-executive Chairman
Slide 6: Key Milestones
66 MARCH 2019 INVESTOR PRESENTATION KEY MILESTONES For personal use only FerriSmart, a ground-breaking artificial intelligence solution for the quantification of liver iron concentration achieved CE Mark, TGA, and FDA regulatory clearance, making it the only regulatory approved artificial intellige
Slide 7: Milestones and Achievements (2018 - Present)
INVESTOR PRESENTATION MARCH 2019 7 AND ACHIEVEMENTS For personal use only (2018 - PRESENT) Eight multi-year contracts executed with pharmaceutical and therapeutic companies for the use of FerriScan and other Resonance Health services for a combined aggregate value of approximately US$2,75 million.
Slide 8: FerriScan by Region and SaaS Business Model
8 MARCH 2019 INVESTOR PRESENTATION FerriScan by Region Software as a Service Africa 1% Asia 8% For personal use only United States 24% Australia & (SaaS) business model New Zealand 9% Canada 9% Under SaaS, the therapeutic companies customer pays for our may contract Resonance services (pay-per-use),
Slide 9: Global Access to FerriScan
MINIMALINVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORTMARCH 2019 TEMPLATE 9 GLOBAL ACCESS TO FERRISCAN For personal use only
Slide 10: Iron Overload Market Fundamentals
1010 ANNUAL MARCHREPORT 2019 TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 IRON OVERLOAD MARKET FUNDAMENTALS For personal use only Total Addressable Market (for FerriScan and FerriSmart) • World Health Organization estimates that over 330,000 affected infants are born annually with iron re
Slide 11: Diagnosis of Iron Overload and Monitoring of Liver Iron
MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORT MARCH 2019 TEMPLATE 1111 FDA mandates an approved ‘com- Inherited hemoglobin disorders, such as thalassemia and panion diagnostic’ to prescribe Ex- jade in Non-Transfusion Dependent sickle cell disease, are now considered among the most Fo
Slide 12: Metabolic Disease Market Fundamentals
1212 ANNUAL2019 MARCH REPORT TEMPLATE MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 METABOLIC DISEASE MARKET FUNDAMENTALS For personal use only Total Addressable Market (for HepaFat-Scan and other fat and metabolic related products) • Non-alcoholic Fatty Liver Disease (NAFLD) affects 10-30% of the g
Slide 13: Diagnosis and Therapy of Fatty Liver Disease
INVESTOR MINIMAL PRESENTATION DESIGN 2016/2107 ANNUAL REPORT MARCH 2019 TEMPLATE 13 Rising global obesity, caused by the consumption of high calorie and For personal use only nutrient poor diets, is increasing the rates of cardiovascular (heart) disease, diabetes, liver disease (NAFLD/NASH), and can
Slide 14: Growth Through Product
14 MARCH 2019 INVESTOR PRESENTATION GROWTH THROUGH PRODUCT For personal use only Product Improvements • Work is underway to calibrate FerriScan to 3 Tesla (3T) scanners: With the increase in use of 3T scanners globally, Resonance Health is adapting FerriScan to ensure 3T compatibility for those clie
Slide 15: Innovation and Collaboration
INVESTOR PRESENTATION MARCH 2019 15 INNOVATION AND COLLABORATION For personal use only Resonance Health has a long history of collaborating with research institutes and private industry partners and continues to assess opportunities for further expansion. Product Innovation and Collaboration • Perth
Slide 16: 2019 HY Results
16 ANNUAL MARCH 2019 REPORT TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 2019 HY RESULTS For personal use only $1,843K $701K* *EBITDA AND NPAT HY 2019 INCLUDES REVENUE EBITDA EMPLOYEE SHARE-BASED PAYMENTS OF $34,804. $2,144K CASH $935k* BALANCE NPAT • Revenue for the HY 18/19 was $1,843k,
Slide 17: Half Year Results Comparison
MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 ANNUAL REPORT MARCH 2019 TEMPLATE 17 HALF YEAR RESULTS COMPARISON ($’000) For personal use only
Slide 18: Revenue by Region
18 18 ANNUAL MARCH 2019 REPORT TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 REVENUE BY REGION For personal use only Australia Canada 3% 7% Europe UK 3% 21% Asia & Middle East 1% USA 65%
Slide 19: Largest Shareholders
MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORT MARCH 2019 TEMPLATE 19 INVESTORS OVERVIEW LARGEST SHAREHOLDERS (AS OF 12 MARCH 2019) Rank Name Units % of Units For personal use only 1 SOUTHAM INVESTMENTS 2003 PTY LTD 73,000,000 18.14 2 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 36,336,30
Slide 20: Contact Details
For personal use only INVESTOR PRESENTATION Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the delivery and development of non-invasive medical imaging software and analysis services. 141 Burswood Road, Burswood WA 6100 Telephone: +61 (0)8 9286 5300 Fax: +61 8 9286 5
Resonance Health — Investor Presentation (March 2019) on 6ix